<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02209948</url>
  </required_header>
  <id_info>
    <org_study_id>GEINO 14-01</org_study_id>
    <secondary_id>2014-000838-39</secondary_id>
    <nct_id>NCT02209948</nct_id>
  </id_info>
  <brief_title>Temozolomide 12 Cycles Versus 6 Cycles of Standard First-line Treatment in Patients With Glioblastoma.</brief_title>
  <official_title>Clinical Trial Phase IIB Randomized, Multicenter, of Continuation or Non Continuation With 6 Cycles of Temozolomide After the First 6 Cycles of Standard First-line Treatment in Patients With Glioblastoma.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Grupo Español de Investigación en Neurooncología</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Grupo Español de Investigación en Neurooncología</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to show if prolonging treatment with temozolomide to 12 cycles
      improve progression-free survival in patients with glioblastoma included in this study,
      randomized according to o6-methylguanine-DNA-methyltransferase (MGMT) methylation status and
      residual disease or not, to receive an additional 6 cycles of temozolomide.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 2014</start_date>
  <completion_date type="Anticipated">January 2019</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival at 6 month</measure>
    <time_frame>6 month</time_frame>
    <description>Number of patients (proportion) without progression of disease and time between start of treatment and progression of disease.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Treatment safety</measure>
    <time_frame>Three years</time_frame>
    <description>Total number of adverse events, type of events and grade</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participant without tumor activity</measure>
    <time_frame>Three years</time_frame>
    <description>It will be measured following RANO guidelines: progression-free survival, progression-free survival at 6 month after the end of treatment and response rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Three years</time_frame>
    <description>Time between start of treatment and death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Corticosteroids dose</measure>
    <time_frame>6 months</time_frame>
    <description>Number of patients that reported with modifications on corticosteroids dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurological status</measure>
    <time_frame>6 months</time_frame>
    <description>Comparison of Barthel questionnaire and Minimental test scores between baseline and 6-months evaluation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants with MGMT methylation</measure>
    <time_frame>Three years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Glioblastoma</condition>
  <arm_group>
    <arm_group_label>Temozolomide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Those patients will take 6 additional Temozolomide cycles</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Without treatment</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Temozolomide</intervention_name>
    <arm_group_label>Temozolomide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Ability to understand and sign the informed consent document .

          2. Age greater than or equal 18.

          3. Patients with glioblastoma according to WHO classification (glioblastoma ) who
             received chemo- radiotherapy and temozolomide -based chemotherapy ( Stupp scheme ) and
             have completed 6 cycles of adjuvant temozolomide (with or without bevacizumab) in the
             context of standard treatment without presenting progression of disease.

          4. Availability of tumor tissue from the first surgery for centralized histological
             review , for determining the MGMT study if you have not done in the center of origin.
             (If they were made in the center of origin the result of the center will be accepted
             ).

          5. Stable dose of dexamethasone in the inclusion never above corticoids dose received in
             cycle 6 of the adjuvant .

          6. Index greater than or equal 60 % Karnofsky.

          7. All patients must show no progression of disease in a brain nuclear magnetic resonance
             (NMR) as defined in RANO established criteria before randomization .

          8. Basal NMR study on a maximum of 6 weeks prior to inclusion, in which no progress is
             observed and is permitted to manage the care 6th cycle ( NMR performed after the 6th
             cycle of adjuvant is also acceptable as long as no progression was observed).

          9. Adequate bone marrow reserve : hematocrit greater or equal 29% , white blood cell&gt;
             3,000 , RAN greater or equal 1,500 cells / ul , platelets greater or equal 100,000
             cells / ul.

         10. Creatinine &lt;1.5 times the upper limit of normal (ULN) of the laboratory performing the
             analysis.

         11. Serum bilirubin &lt;1.5 / ULN; SGOT , SGPT &lt; 2.5 times the upper limit of normal of the
             laboratory performing the analysis. Serum &lt; 3/ULN alkaline phosphatases .

         12. Effective contraceptive method in patients and their partners.

        Exclusion Criteria:

          1. Less than 5 years of any previous invasive neoplasia. In situ cervical carcinoma or
             basal cell skin carcinoma accepted.

          2. Concomitant treatment with other investigational agents (other concomitant
             bevacizumab) .

          3. Presence of any clinically significant gastrointestinal abnormalities that may affect
             the decision , transit or absorption of study drug , such as the inability to take
             medication in tablets by mouth.

          4. Presence of any psychiatric or cognitive disorder that limits understanding or written
             informed consent and / or impair compliance with the requirements of this protocol.

          5. Concurrent disease that prevents the continuation of temozolomide treatment.

          6. Presence of leptomeningeal dissemination.

          7. Pregnant or breastfeeding.

          8. Positive patients receiving combination antiretroviral therapy in HIV
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carmen Balañá, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital Germnas Trias i Pujol- ICO Badalona</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mª Ángeles Vaz, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital Universitario Ramon y Cajal</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Federico Nepote</last_name>
    <phone>0034 934 34 44 12</phone>
    <email>investigacion@mfar.net</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Verónica Roca</last_name>
    <phone>0034 934 34 44 12</phone>
    <email>investigacion@mfar.net</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Germans Trias i Pujol</name>
      <address>
        <city>Badalona</city>
        <state>Barcelona</state>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ana Márquez, Pharmacist</last_name>
      <phone>0034 934 33 44 12</phone>
      <email>ana.marquez@mfar.net</email>
    </contact>
    <investigator>
      <last_name>Carmen Balañá, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Català D'Oncologia L'Hospitalet (Ico)</name>
      <address>
        <city>L'Hospitalet de Llobregat</city>
        <state>Barcelona</state>
        <zip>08908</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ana Márquez, Pharmacist</last_name>
      <phone>+34934344412</phone>
      <email>ana.marquez@mfar.net</email>
    </contact>
    <investigator>
      <last_name>Carles Mesia, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Fundación Alcorcón</name>
      <address>
        <city>Alcorcón</city>
        <state>Madrid</state>
        <zip>28922</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Son Espases</name>
      <address>
        <city>Palma de Mallorca</city>
        <state>Mallorca</state>
        <zip>07010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ana Márquez, Pharmacist</last_name>
      <phone>+34 934344412</phone>
      <email>ana.marquez@mfar.net</email>
    </contact>
    <investigator>
      <last_name>Jose Fuster, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Sant Joan de Reus</name>
      <address>
        <city>Reus</city>
        <state>Tarragona</state>
        <zip>43204</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ana Márquez, Pharmacist</last_name>
      <phone>+34 934344412</phone>
      <email>ana.marquez@mfar.net</email>
    </contact>
    <investigator>
      <last_name>Sergio Peralta, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Consorcio Hospitalario Provincial de Castellón</name>
      <address>
        <city>Castelló</city>
        <state>Valencia</state>
        <zip>12002</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Del Mar</name>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital de La Santa Creu I Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Clínic de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ana Márquez, Pharmacist</last_name>
      <phone>+34 934344412</phone>
      <email>ana.marquez@mfar.net</email>
    </contact>
    <investigator>
      <last_name>Estela Pineda, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital General de Ciudad Real</name>
      <address>
        <city>Ciudad Real</city>
        <zip>13005</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Dr. Josep Trueta de Girona</name>
      <address>
        <city>Girona</city>
        <zip>17007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ana Márquez, Pharmacist</last_name>
      <phone>+34 934344412</phone>
      <email>ana.marquez@mfar.net</email>
    </contact>
    <investigator>
      <last_name>Sonia del Barco, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Arnau de Vilanova</name>
      <address>
        <city>Lleida</city>
        <zip>25198</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Lucus Augusti</name>
      <address>
        <city>Lugo</city>
        <zip>27003</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ana Márquez, Pharmacist</last_name>
      <phone>+34 934344412</phone>
      <email>ana.marquez@mfar.net</email>
    </contact>
    <investigator>
      <last_name>Marta Covela, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Ramón Y Cajal</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ana Márquez, Pharmacist</last_name>
      <phone>+34934344412</phone>
      <email>ana.marquez@mfar.net</email>
    </contact>
    <investigator>
      <last_name>M Angeles Vaz Salgado, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico San Carlos</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Universitario de Salamanca</name>
      <address>
        <city>Salamanca</city>
        <zip>37007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ana Márquez, Pharmacist</last_name>
      <phone>+34 934344412</phone>
      <email>ana.marquez@mfar.net</email>
    </contact>
    <investigator>
      <last_name>Luis Miguel Navarro, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen del Rocío</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ana Márquez, Pharmacist</last_name>
      <phone>+34 934344412</phone>
      <email>ana.marquez@mfar.net</email>
    </contact>
    <investigator>
      <last_name>Begoña Pérez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Consorcio Hospital General Universitario de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46014</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ana Márquez, Pharmacist</last_name>
      <phone>+34 934344412</phone>
      <email>ana.marquez@mfar.net</email>
    </contact>
    <investigator>
      <last_name>Alfonso Berrocal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Miguel Servet</name>
      <address>
        <city>Zaragoza</city>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ana Márquez, Pharmacist</last_name>
      <phone>+34 934344412</phone>
      <email>ana.marquez@mfar.net</email>
    </contact>
    <investigator>
      <last_name>Ana Herrero, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 4, 2014</study_first_submitted>
  <study_first_submitted_qc>August 5, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 6, 2014</study_first_posted>
  <last_update_submitted>March 14, 2018</last_update_submitted>
  <last_update_submitted_qc>March 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Temozolomide</mesh_term>
    <mesh_term>Dacarbazine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

